The NLRP3 inflammasome as a target for sensorineural hearing loss

被引：18

作者：

Gregory, Grace E. ^{[1
,2
,3
]}

Munro, Kevin J. ^{[4
,5
]}

Couper, Kevin N. ^{[2
,3
]}

Pathmanaban, Omar N. ^{[1
,2
,3
,6
]}

Brough, David ^{[1
,2
,3
]}

机构：

[1] Univ Manchester, Fac Biol Med & Hlth, Sch Biol Sci, Div Neurosci,Manchester Acad Hlth Sci Ctr, Manchester, England

[2] Univ Manchester, Geoffrey Jefferson Brain Res Ctr, Manchester Acad Hlth Sci Ctr, Northern Care Alliance NHS Grp, Manchester, England

[3] Univ Manchester, Lydia Becker Inst Immunol & Inflammat, Manchester, England

[4] Univ Manchester, Manchester Ctr Audiol & Deafness, Sch Hlth Sci, Manchester, England

[5] Manchester Univ Hosp NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester, England

[6] Salford Royal Hosp NHS Fdn Trust, Manchester Ctr Clin Neurosci, Dept Neurosurg, Salford, England

来源：

CLINICAL IMMUNOLOGY | 2023年 / 249卷

基金：

英国医学研究理事会;

关键词：

Sensorineural hearing loss; Inflammation; Cochlea; NLRP3; inflammasome; Interleukin-1;

D O I：

10.1016/j.clim.2023.109287

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Sensorineural hearing loss is the most common type of hearing loss in adults and occurs due to damage of the inner ear caused by a range of factors including ageing, excessive noise, toxins, and cancer. Auto-inflammatory disease is also a cause of hearing loss and there is evidence that inflammation could contribute to hearing loss in other conditions. Within the inner ear there are resident macrophage cells that respond to insults and whose activation correlates with damage. The NLRP3 inflammasome is a multi-molecular pro-inflammatory protein complex that forms in activated macrophages and may contribute to hearing loss. The aim of this article is to discuss the evidence for the NLRP3 inflammasome and associated cytokines as potential therapeutic targets for sensorineural hearing loss in conditions ranging from auto-inflammatory disease to tumour-induced hearing loss in vestibular schwannoma.

引用

页数：5

共 50 条

[31] Therapeutic potential of the target on NLRP3 inflammasome in multiple sclerosis
Shao, Shuai
Chen, Chengjuan
Shi, Gaona
Zhou, Yu
Wei, Yazi
Fan, Ningyu
Yang, Yan
Wu, Lei
Zhang, Tiantai
PHARMACOLOGY & THERAPEUTICS, 2021, 227
[32] The Potential of NLRP3 Inflammasome as a Therapeutic Target in Neurological Diseases
He, Wenfang
Hu, Zhiping
Zhong, Yanjun
Wu, Chenfang
Li, Jinxiu
MOLECULAR NEUROBIOLOGY, 2023, 60 (05) : 2520 - 2538
[33] The NLRP3 inflammasome as a new target in respiratory disorders treatment
Leszczynska, Katarzyna
Jakubczyk, Dominika
Gorska, Sabina
FRONTIERS IN IMMUNOLOGY, 2022, 13
[34] The NLRP3 Inflammasome as a Novel Therapeutic Target for Cardiac Fibrosis
Fan, Jiwen
Ren, Meng
Adhikari, Binay Kumar
Wang, Haodong
He, Yuquan
JOURNAL OF INFLAMMATION RESEARCH, 2022, 15 : 3847 - 3858
[35] NLRP3 Inflammasome: A Potential Alternative Therapy Target for Atherosclerosis
Liu Yang
Li Chao
Yin Honglin
Zhang Xinrong
Li Yunlun
EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2020, 2020
[36] Natural Products that Target the NLRP3 Inflammasome to Treat Fibrosis
Ding, Nan
Wei, Bo
Fu, Xiaohui
Wang, Chuan
Wu, Yimou
FRONTIERS IN PHARMACOLOGY, 2020, 11
[37] NLRP3 inflammasome as a novel target for cystic fibrosis treatment
Merve Atalay
Başak Şen
Didem Dayangaç Erden
Bulletin of the National Research Centre, 47 (1)
[38] The role of NLRP3 inflammasome in sepsis: A potential therapeutic target
He, Wenfang
Dong, Haiyun
Wu, Chenfang
Zhong, Yanjun
Li, Jinxiu
INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 115
[39] The NLRP3 inflammasome, a target for therapy in diverse disease states
Cook, Graham P.
Savic, Sinisa
Wittmann, Miriam
McDermott, Michael F.
EUROPEAN JOURNAL OF IMMUNOLOGY, 2010, 40 (03) : 631 - 634
[40] NLRP3 inflammasome: A likely target for the treatment of allergic diseases
Xiao, Yichen
Xu, Wenna
Su, Wenru
CLINICAL AND EXPERIMENTAL ALLERGY, 2018, 48 (09) : 1080 - 1091

← 1 2 3 4 5 →